Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8:454–63. https://doi.org/10.1002/prca.201300095.

Article  CAS  PubMed  Google Scholar 

Altmann A, Haberkorn U, Siveke J. The latest developments in imaging of fibroblast activation protein. J Nucl Med. 2021;62:160–7. https://doi.org/10.2967/jnumed.120.244806.

Article  CAS  PubMed  Google Scholar 

Moon ES, Elvas F, Vliegen G, De Lombaerde S, Vangestel C, De Bruycker S, et al. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA(5m) chelators. EJNMMI Radiopharm Chem. 2020;5:19. https://doi.org/10.1186/s41181-020-00102-z.

Article  PubMed  PubMed Central  Google Scholar 

Watabe T, Liu Y, Kaneda-Nakashima K, Shirakami Y, Lindner T, Ooe K, et al. Theranostics targeting fibroblast activation protein in the tumor stroma: (64)Cu- and (225)Ac-labeled FAPI-04 in pancreatic cancer xenograft mouse models. J Nucl Med. 2020;61:563–9. https://doi.org/10.2967/jnumed.119.233122.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kosmala A, Serfling SE, Dreher N, Lindner T, Schirbel A, Lapa C, et al. Associations between normal organs and tumor burden in patients imaged with fibroblast activation protein inhibitor-directed positron emission tomography. Cancers (Basel). 2022;14. https://doi.org/10.3390/cancers14112609.

Privé BM, Boussihmad MA, Timmermans B, van Gemert WA, Peters SMB, Derks YHW, et al. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Eur J Nucl Med Mol Imaging. 2023;50:1906–18. https://doi.org/10.1007/s00259-023-06144-0.

Article  PubMed  PubMed Central  Google Scholar 

Ferdinandus J, Costa PF, Kessler L, Weber M, Hirmas N, Kostbade K, et al. Initial clinical experience with (90)Y-FAPI-46 radioligand therapy for advanced-stage solid tumors: a case series of 9 patients. J Nucl Med. 2022;63:727–34. https://doi.org/10.2967/jnumed.121.262468.

Article  PubMed  PubMed Central  Google Scholar 

Moon ES, Ballal S, Yadav MP, Bal C, Van Rymenant Y, Stephan S, et al. Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time. Am J Nucl Med Mol Imaging. 2021;11:476–91.

CAS  PubMed  PubMed Central  Google Scholar 

Millul J, Koepke L, Haridas GR, Sparrer KMJ, Mansi R, Fani M. Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides. Eur J Nucl Med Mol Imaging. 2023. https://doi.org/10.1007/s00259-023-06272-7.

Article  PubMed  PubMed Central  Google Scholar 

Yadav MP, Ballal S, Martin M, Roesch F, Satapathy S, Moon ES, et al. Therapeutic potential of [177Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessment. Eur J Nucl Med Mol Imaging. 2023. https://doi.org/10.1007/s00259-023-06482-z.

Article  PubMed  Google Scholar 

Galbiati A, Zana A, Bocci M, Millul J, Elsayed A, Mock J, et al. A dimeric FAP-targeting small-molecule radioconjugate with high and prolonged tumor uptake. J Nucl Med. 2022;63:1852–8. https://doi.org/10.2967/jnumed.122.264036.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao L, Niu B, Fang J, Pang Y, Li S, Xie C, et al. Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of (68)Ga-labeled FAPI dimer. J Nucl Med. 2022;63:862–8. https://doi.org/10.2967/jnumed.121.263016.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao L, Chen J, Pang Y, Fang J, Fu K, Meng L, et al. Development of fibroblast activation protein inhibitor-based dimeric radiotracers with improved tumor retention and antitumor efficacy. Mol Pharm. 2022;19:3640–51. https://doi.org/10.1021/acs.molpharmaceut.2c00424.

Article  CAS  PubMed  Google Scholar 

Loktev A, Lindner T, Burger EM, Altmann A, Giesel F, Kratochwil C, et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J Nucl Med. 2019;60:1421–9. https://doi.org/10.2967/jnumed.118.224469.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhong X, Guo J, Han X, Wu W, Yang R, Zhang J, et al. Synthesis and preclinical evaluation of a novel FAPI-04 dimer for cancer theranostics. Mol Pharm. 2023;20:2402–14. https://doi.org/10.1021/acs.molpharmaceut.2c00965.

Article  CAS  PubMed  Google Scholar 

Li H, Ye S, Li L, Zhong J, Yan Q, Zhong Y, et al. (18)F- or (177)Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retention. Eur J Nucl Med Mol Imaging. 2022;49:2705–15. https://doi.org/10.1007/s00259-022-05757-1.

Article  CAS  PubMed  Google Scholar 

Zhao L, Chen J, Pang Y, Fu K, Shang Q, Wu H, et al. Fibroblast activation protein-based theranostics in cancer research: a state-of-the-art review. Theranostics. 2022;12:1557–69. https://doi.org/10.7150/thno.69475.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. (68)Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60:386–92. https://doi.org/10.2967/jnumed.118.215913.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ballal S, Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S, et al. Biodistribution, pharmacokinetics, dosimetry of [(68)Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [(18)F]F-FDG PET/CT in patients with various cancers. Eur J Nucl Med Mol Imaging. 2021;48:1915–31. https://doi.org/10.1007/s00259-020-05132-y.

Loktev A, Lindner T, Mier W, Debus J, Altmann A, Jager D, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59:1423–9. https://doi.org/10.2967/jnumed.118.210435.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Assadi M, Rekabpour SJ, Jafari E, Divband G, Nikkholgh B, Amini H, et al. Feasibility and therapeutic potential of 177Lu-fibroblast activation protein inhibitor-46 for patients with relapsed or refractory cancers: a preliminary study. Clin Nucl Med. 2021;46:e523–30. https://doi.org/10.1097/RLU.0000000000003810.

Article  PubMed  Google Scholar 

Li ZB, Chen K, Chen X. (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging. 2008;35:1100–8. https://doi.org/10.1007/s00259-007-0692-y.

Article  CAS  PubMed  Google Scholar 

Zang J, Wen X, Lin R, Zeng X, Wang C, Shi M, et al. Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [(68)Ga]Ga-FAPI-RGD. Theranostics. 2022;12:7180–90. https://doi.org/10.7150/thno.79144.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pang Y, Zhao L, Fang J, Chen J, Meng L, Sun L, et al. Development of FAPI tetramers to improve tumor uptake and efficacy of FAPI radioligand therapy. J Nucl Med. 2023:jnumed.123.265599. https://doi.org/10.2967/jnumed.123.265599.

Lang L, Li W, Guo N, Ma Y, Zhu L, Kiesewetter DO, et al. Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem. 2011;22:2415–22. https://doi.org/10.1021/bc200197h.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang RH, Guo HY, Deng H, Li J, Quan ZS. Piperazine skeleton in the structural modification of natural products: a review. J Enzyme Inhib Med Chem. 2021;36:1165–97. https://doi.org/10.1080/14756366.2021.1931861.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, et al. Radiation dosimetry and biodistribution of (68)Ga-FAPI-46 PET imaging in cancer patients. J Nucl Med. 2020;61:1171–7. https://doi.org/10.2967/jnumed.119.236786.

Article  CAS  PubMed  PubMed Central  Google Scholar